Every S-3 that Tempest Therapeutics, Inc. (TPST) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow TPST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TPST filings page.
Tempest Therapeutics, Inc. (TPST) is registering up to 9,534,164 shares of common stock for resale by selling stockholders after the registration statement becomes effective. Tempest is not selling securities under the prospectus and will receive no proceeds from stockholder resales.
Tempest may receive proceeds if warrants are exercised for cash; if all warrants are exercised for cash in full, gross proceeds would be approximately $5.22 million. Net proceeds from any warrant exercises are intended for working capital and general corporate purposes. Pre-Funded Warrants became exercisable immediately after the September 15, 2026 closing at $0.001 per share. Series C and D Warrants have a $0.805 per-share exercise price and become exercisable when stockholder approval takes effect; Tempest agreed to seek that approval within 90 days after September 11, 2026.
Exercise limits are 9.99% for Pre-Funded Warrants and 4.99% for Common Warrants, with an option to raise the Common Warrant limit to 9.99%. The 2025 audited financial statements include an auditor paragraph describing conditions that raise substantial doubt about Tempest's ability to continue as a going concern.
Tempest Therapeutics, Inc. is registering up to 2,426,897 shares of common stock for resale by selling stockholders pursuant to a prospectus dated June 26, 2026. The registered shares consist of 2,344,828 shares issuable upon exercise of newly issued common stock purchase warrants and 82,069 shares issuable upon exercise of placement agent warrants. The registration covers resale by the warrant holders; the company is not selling shares here and will not receive proceeds from resales, though it will receive cash proceeds if the Warrants are exercised. If all Warrants were exercised for cash in full, gross proceeds to the company would be approximately $4.23 million. The prospectus discloses 15,979,411 shares outstanding as of June 18, 2026 used for percentage calculations and states a Nasdaq closing price of $1.05 per share on June 25, 2026. The New Warrants have an exercise price of $1.73, become exercisable upon required Nasdaq stockholder approval, and expire on May 29, 2028. The New Warrants and Placement Agent Warrants include customary adjustment provisions, cashless exercise mechanics, and holder election beneficial ownership limits of 4.99% or 9.99%.
Tempest Therapeutics, Inc. is registering the resale of up to 2,777,781 shares of its common stock by selling stockholders.
The registration covers shares issued in a March 20, 2026 private placement (including 462,964 issued shares, 925,927 Series A Warrant shares, 925,927 Series B Warrant shares and 462,963 Pre-Funded Warrant shares). The company will not receive proceeds from resale of these shares. Shares outstanding were 14,344,034 as of March 30, 2026.
Tempest Therapeutics, Inc. is registering for resale up to 8,268,495 shares of its common stock on behalf of selling stockholders who received the shares under an Asset Purchase Agreement.
The prospectus states the Shares were issued in connection with the acquisition of CAR-T and related assets from Erigen LLC and Factor Bioscience Inc.; the company will not receive proceeds from resales. The prospectus discloses 14,344,034 shares outstanding as of March 25, 2026 and cites a closing market price of $1.73 per share on March 27, 2026. The registration statement is a shelf Form S-3 registration enabling resale "from time to time" by the named selling stockholders and any permitted transferees.